Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right

Jan 17 2017

• By Anju Ghangurde

Pharma pills

Related Content

Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2

Oct 26 2016

JPM 2016: Cipla Shapes Respiratory Build-Up

Jan 26 2016

Cipla Injects Scale With $550m US Buy

Sep 07 2015

Cipla Sees Changed Profile; Wraps Up Europe Revamp

Sep 29 2016

India Pharma 2017: 3Cs And D (Disruption)?

Jan 13 2017

Related Companies

Cipla Limited

Lupin Limited

Dr. Reddy's Laboratories Ltd.

Cipla Limited

Exelan Pharmaceuticals Inc.

Sun Pharmaceutical Industries Ltd.

Additional Topics

United States Commercial Strategy Generic Drugs Respiratory BioPharmaceutical

More from Business

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window